We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
New authorities granted to the FDA in 2012 that stiffened penalties for drug counterfeiters are failing to curb the problem of fake drugs because they do not apply to distributors of counterfeits. Read More
The FDA says sponsors of antiretroviral drugs should submit clinical trial data sets that include patient data, endpoint data, genotypic data and phenotypic data when reporting data on HIV-1 resistance to the agency in support of an HIV drug. Read More
Drugmakers seeking marketing authorization in Australia will soon be able to make complete submissions in electronic format, allowing for cost savings and potentially swifter reviews. Read More
As calls for revoking the FDA’s approval of Zogenix’s painkiller Zohydro ER continue to grow, lawmakers are now questioning whether a public-private industry partnership tainted the agency approval process. Read More
The FDA’s monitoring of in-house emails of five agency whistleblowers that went public with product safety complaints was not supported by agency policy and may have violated the Fourth Amendment and the Whistleblower Protection Act, House Republicans and an HHS watchdog charged Wednesday. Read More
The FDA is proposing that physicians be allowed to perform fecal matter transplants (FMT) in limited circumstances without an investigational new drug (IND) application, provided the physician or their patient knows the donor. Read More
FDA advisors Wednesday urged the agency to rescind the OTC bronchodilator monograph for epinephrine and racepinephrine products delivered via a hand-held rubber bulb nebulizer, saying the combination products present safety concerns that only an NDA can address. Read More
Following recommendations from the FDA, the Drug Enforcement Administration (DEA) is proposing to establish tighter controls on hydrocodone combination drug products such as Vicodin. Read More